Lv51
854 积分 2022-08-10 加入
Development of RMC-6236, a potent and orally bioavailable RAS(ON) multi-selective tri-complex inhibitor for the treatment of RAS-addicted cancers by targeting multiple RAS variants
22天前
已完结
Discovery of selective NaV1.8 inhibitors based on 5-chloro-2-(4,4-difluoroazepan-1-yl)-6-methyl nicotinamide scaffold for the treatment of pain
22天前
已完结
A simple and sensitive ultra‐high performance liquid chromatography tandem mass spectrometry method for the quantitative analysis of VX‐548 in monkey plasma: Method validation and application to pharmacokinetic study
22天前
已完结
Gender difference in the pharmacokinetics and metabolism of VX‐548 in rats
22天前
已完结
AlphaFold2 structures guide prospective ligand discovery
1个月前
已完结
State-of-the-art and upcoming trends in RAS-directed therapies in gastrointestinal malignancies
2个月前
已完结
Drugging RAS: Moving Beyond KRASG12C
2个月前
已完结
Mechanisms of response and tolerance to active RAS inhibition in KRAS-mutant NSCLC
2个月前
已完结
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
2个月前
已完结
Ligand-controlled regiodivergent direct arylation of indoles via oxidative boron Heck reaction
2个月前
已完结
皖公网安备34019202002308
